STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
